Innate Pharma SA (IPHA) — research page

US · us-cm-kg/NASDAQ/IPHA · as of 2026-11-08

Identity and listing

Innate Pharma SA is listed on NASDAQ under the ticker IPHA, with ISIN US45781K2042. The record holds no LEI, as no GLEIF record with the exact legal name in jurisdiction US-I0 is on the record. The security type is Non-operating entity type (other), the sector is 2836 Biological Products, (No Diagnostic Substances), and the jurisdiction is France. The segment is not on the record. The issuer is listed and not halted.

The disclosure read

The record holds 41 filings in the twelve months to 2026-11-08, across 38 filing days. Of these, 4 are regulatory filings and 37 are results. The median gap between filing days is 6 days. The latest filing is dated 2026-11-05, is of type results, and sits 3 days before the record date. The NASDAQ exchange median is 52 filings, a cadence gap of 6.0 days, and a latency of 5.0 days across 4359 issuers. The sector median is 65.5 filings, a cadence gap of 5.5 days, and a latency of 4.0 days across 176 issuers. The issuer's 41 filings are below the exchange median of 52 and below the sector median of 65.5.

window 2025-11-08 to 2026-11-08 · the node's disclosure lines, as get_filings serves them

Auditor

The auditor of record is not on the record, as the latest annual report cover carries no dei:AuditorName tag, and foreign private issuers and older filings carry none. The auditor location is not on the record. The record holds no auditor changes.

Events and halts

The record holds no listing, delisting or name change lines for the issuer. The domicile change is not on the record, as EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, as the exchanges' tier transfers are not EDGAR filings. The halt flag is clear: listed, not halted.

Orderability

The outcome is not determinable under rule version acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, as of chapter date 2026-11-04. The chapter's orderability section carries no client_categories, so the outcome cannot name its client category.

rule acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1 · chapter as of 2026-11-04 · the full outcome: get_orderability

Coverage

The issuer's own investor-relations page names 7 research houses: BTIG, H.C. Wainwright & Co., Leerink, Lucid Capital Markets, Oddo Securities, Portzamparc and Stifel.

Open research

No openly published research notes were found on the record for the issuer.

Licensed

Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.

As-of depth

The issuer's years 2021, 2022, 2023, 2024, 2025 and 2026 are sealed. The market's earliest sealed date is 2021-01-04. The live record began on 2026-09-12.

Sources

8 source pages are named on this page; every value above carries its own source page and read date in the numbers.

10.1

https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)

10.2

https://www.sec.gov/data-research/sec-markets-data/fails-deliver-data (identity.isin)

10.3

https://data.sec.gov/submissions/CIK0001598599.json (identity.jurisdiction)

10.4

https://mcp.us-cm-kg.ai/events/NASDAQ/IPHA (the disclosure lines)

10.5

https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)

10.6

https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)

10.7

https://investors.innate-pharma.com/English/investors/stock-info/analyst-coverage/default.aspx (coverage)

10.8

https://mcp.us-cm-kg.ai/record/NASDAQ/IPHA (the record)

Read it by agent

The same page, signed and receipted: get_research at https://mcp.getissuer.ai/mcp with {"isin":"US45781K2042"}. Twins: .md · .json. Written: Claude through the platform account, Haiku class; one pass; checked against the numbers. Page hash sha256:e3db765c109c6de4.